RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Benitec strengthens patent position in RNAi

Benitec strengthens patent position in RNAi

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

Arrowhead increases ownership in Calando's outstanding equity to 79%

Arrowhead increases ownership in Calando's outstanding equity to 79%

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Silence provides year-end update on trading and offer-period

Silence provides year-end update on trading and offer-period

RXi's dermal anti-scarring candidate selected to advance into development

RXi's dermal anti-scarring candidate selected to advance into development

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

EPO upholds Alnylam's Tuschl II 1407044 patent

EPO upholds Alnylam's Tuschl II 1407044 patent

Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics

Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics

USPTO, EPO issue key patents for Tekmira's LNP technology

USPTO, EPO issue key patents for Tekmira's LNP technology

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Access Pharmaceuticals to present two oncology posters at CPR Conference

Access Pharmaceuticals to present two oncology posters at CPR Conference

RXi third quarter net loss increases to $4.1 million

RXi third quarter net loss increases to $4.1 million

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation